Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Applied Therapeutics Inc | APLT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.74 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.74 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.88 - 9.39 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.74 | USD |
Applied Therapeutics (APLT) Options Flow Summary
Applied Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 501.9M | 105.89M | - | 9.99M | -119.76M | -1.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Applied Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APLT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.32 | 5.41 | 4.65 | 4.98 | 765,415 | -0.58 | -10.90% |
| 1 Month | 6.87 | 7.39 | 4.65 | 5.94 | 895,547 | -2.13 | -31.00% |
| 3 Months | 2.91 | 9.39 | 2.585 | 5.58 | 1,868,209 | 1.83 | 62.89% |
| 6 Months | 2.49 | 9.39 | 1.79 | 4.28 | 1,563,024 | 2.25 | 90.36% |
| 1 Year | 0.88 | 9.39 | 0.88 | 3.57 | 1,114,838 | 3.86 | 438.64% |
| 3 Years | 16.605 | 25.59 | 0.4995 | 3.59 | 535,736 | -11.87 | -71.45% |
| 5 Years | 8.04 | 57.39 | 0.4995 | 7.44 | 379,633 | -3.30 | -41.04% |
Applied Therapeutics Description
| Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. |
